NCT01233882 - Bosutinib In Subjects With Renal Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Renal Disease, End-StageRenal Insufficiency, ChronicRenal Insufficiency, Acute

Interventions

DRUG

Bosutinib

Single dose of 200 mg of bosutinib in subjects with normal renal function

DRUG

Bosutinib

Single dose of 200 mg of bosutinib in subjects with mild renal impairment

DRUG

Bosutinib

Single dose of 200 mg of bosutinib in subjects with moderate renal impairment

DRUG

Bosutinib

Single dose of 200 mg of bosutinib in subjects with severe renal impairment

Trial Locations (5)

Pfizer Investigational Site, Gainesville

Pfizer Investigational Site, DeLand

Pfizer Investigational Site, Orlando

Pfizer Investigational Site, Miami

Pfizer Investigational Site, Saint Paul